Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 4,112 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Post Operative Pain, Urolithiasis, Ureter Calculi, Stent Complication
Interventions: intra-nasal ketorolac, oral diclofenac; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Burns, Wound Infection
Interventions: Methylene Blue, Blue Light Illumination; Drug · Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Pneumonia
Interventions: Experimental Oral Nutritional Supplement; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 55 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Mobile, Alabama • Chicago, Illinois • Springfield, Illinois + 9 more

Conditions: Smoking Cessation
Interventions: Connect Smokers to Treatment 1, Connect Smokers to Treatment 2, Connect Smokers to Treatment 3, Connect Smokers to Treatment 4, Connect Smokers to Treatment 5, Connect Smokers to Treatment 6; Behavioral
Lead sponsor: Minnesota Department of Health; Government
Eligibility: Female only
Enrollment: 3,723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Substance Abuse
Interventions: CASPAR/Treatment Planning; Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 7
States / cities: Camden, New Jersey • Cape May Court House, New Jersey • Collingswood, New Jersey + 4 more

Conditions: Peripheral Vascular Disease
Interventions: Absolute Pro™ Peripheral Self-Expanding Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Sickle Cell Disease
Interventions: AB1; Drug
Lead sponsor: Nirmish Shah; Other
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina

Conditions: Frailty, Frail Elderly, Occupational Therapy, Activities of Daily Living, Home Health Care, Functional Status, Physical Functional Performance, Rehabilitation, Treatment Outcome, Health Services for the Aged
Interventions: ADL-enhanced program, Usual home health rehabilitation therapy; Other
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 100 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Nutritional Assessment
Interventions: Validation of the PortionSize app; Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 7 Years to 12 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Major Depressive Disorder, Miscarriage, Stillbirth, Neonatal Death
Interventions: Group Interpersonal Psychotherapy (IPT-G), Coping with Depression (CWD); Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infections
Interventions: rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349]); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 24 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2009
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: Depression, Post-traumatic Stress Disorder, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: support group therapy, educational intervention; Procedure · Other
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Nevada City, California • Stanford, California

Conditions: Alcohol Drinking, Telemedicine
Interventions: A-CHESS self-monitored, A-CHESS peer-supported, A-CHESS clinically-integrated; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 100 Years
Enrollment: 558 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Shoulder Dystocia
Interventions: Yaari Extractor; Device
Lead sponsor: FetalEase Ltd.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Miami, Florida • Idaho Falls, Idaho • Winston-Salem, North Carolina + 1 more

Conditions: Patient Satisfaction, Pulmonary Rehabilitation
Interventions: TrachPhone Heat Moisture Exchange, Trach Collar; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Fabry Disease
Interventions: pegunigalsidase alfa; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more

Conditions: Atopic Dermatitis
Interventions: GHZ339, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more

Conditions: Opioid-use Disorder, Medication Adherence, Health Care Utilization
Interventions: Behavioral Activation (BA) Therapy, Substance Abuse and Health Navigation Counseling, Medications for Opioid Use Disorder; Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Healthy Subjects
Interventions: Marketed paracetamol, Experimental paracetamol formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obstructive Sleep Apnea, Sleep Apnea, Sleep Apnea, Obstructive, Sleep, Sleep Disorder
Interventions: Eszopiclone, Supplemental Oxygen, Continuous Positive Airway Pressure (CPAP); Drug · Other · Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years to 65 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma
Interventions: CCW702; Drug
Lead sponsor: Calibr, a division of Scripps Research; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: San Diego, California • Baltimore, Maryland • Detroit, Michigan + 2 more

Conditions: Central Nervous System Diseases, Pediatric Disorder, Body Indication
Interventions: Gadopiclenol; Drug
Lead sponsor: Guerbet; Industry
Eligibility: Up to 23 Months
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Cincinnati, Ohio • Charleston, South Carolina

Conditions: Neisseria Gonorrheae Infection
Interventions: Investigational Reflex Test 1, Investigational Reflex Test 2, Investigational Reflex Test 3; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 2,627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Indianapolis, Indiana • Jackson, Mississippi + 5 more

Conditions: Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-Naive B Cell Malignancies
Interventions: TL-895, Navtemadlin; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Columbus, Ohio • Germantown, Tennessee

Search by objective public record fields.

Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection

Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients

Factorial Design to Assess Quit-line Connections

Linking Services to Patient Needs for Improved Patient Outcomes (CASPAR)

Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.

AB1 in Adult Patients With Sickle Cell Disease (SCD)

Synergizing Home Health Rehabilitation Therapy

Validity of the PortionSize App to Measure Children's Food Intake

Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

Phase I: At-Home Support for Rural Women Using Group Video Calling

Mobile Health for Alcohol Use Disorders in Clinical Practice

Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia

Randomized Clinical Trial of the Application of TrachPhone HME and the Impact on Patient Satisfaction for Tracheostomized Head and Neck Cancer Patients

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder

Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend

Do Endotypes Predict Response and Sequelae in OSA Patients

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects